OutSee
OutSee is a genomics-led discovery company that leverages a unique AI engine called Nomaly to predict disease and phenotype directly from a single genome without relying on known genetic associations. Their technology uncovers fundamental biological mechanisms driving disease, enabling discovery beyond standard genomic analysis methods. OutSee's approach excels in precision medicine by predicting complex genetic interactions and grouping patients in novel ways, especially effective for small and large cohorts and rare diseases. The company is based in Cambridge, United Kingdom, and focuses on advancing therapeutic target discovery and precision medicine through innovative computational genomics.
OutSee
OutSee is a genomics-led discovery company that leverages a unique AI engine called Nomaly to predict disease and phenotype directly from a single genome without relying on known genetic associations. Their technology uncovers fundamental biological mechanisms driving disease, enabling discovery beyond standard genomic analysis methods. OutSee's approach excels in precision medicine by predicting complex genetic interactions and grouping patients in novel ways, especially effective for small and large cohorts and rare diseases. The company is based in Cambridge, United Kingdom, and focuses on advancing therapeutic target discovery and precision medicine through innovative computational genomics.
TL;DR
HQ: Cambridge, United Kingdom
Founded: 2023
Product: Nomaly — a predictive genomics AI engine that infers disease and phenotype from a single genome
Recent funding: Seed £1,800,000 (Jun 24, 2025)
Founder / CEO: Julian Gough
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Computational genomics for therapeutic target discovery and precision medicine; predicting disease/phenotype from individual genomes.
Founded
2023
Industry
Biotechnology Research
Tech Stack
Funding Track Record
£1,800,000
Participants reported to include Kadmos Capital, Empirical Ventures, and Panacea Ventures.
Investor Signal
“Seed round led by Ahren Innovation Capital with participation from Kadmos Capital, Empirical Ventures, and Panacea Ventures; Dealroom also lists University of Bristol among investor/shareholder entities.”